Literature DB >> 11007795

The amino-terminal part of PRELP binds to heparin and heparan sulfate.

E Bengtsson1, A Aspberg, D Heinegard, Y Sommarin, D Spillmann.   

Abstract

PRELP (proline, arginine-rich end leucine-rich repeat protein) is an extracellular matrix leucine-rich repeat protein. The amino-terminal region of PRELP differs from that of other leucine-rich repeat proteins in containing a high number of proline and arginine residues. The clustered proline and basic residues are conserved in rat, bovine, and human PRELP. Although the function of PRELP is not yet known, the clustered arginine residues suggest a heparan sulfate/heparin-binding capacity. We show here that PRELP indeed binds heparin and heparan sulfate. Truncated PRELP without the amino-terminal region does not bind heparin. The dissociation constant for the interaction of PRELP with heparin was determined by an in solution binding assay and by surface plasmon resonance analysis to be in the range of 10-30 nm. A 6-mer heparin oligosaccharide was the smallest size showing binding to PRELP. The binding increased with increasing length up to an 18-mer and depended on the degree of sulfation of heparin as well as heparan sulfate. Sulfate groups at all positions were shown to be of importance for the binding. Fibroblasts bind PRELP, and this interaction is inhibited with heparin, suggesting a function for PRELP as a linker between the matrix and cell surface proteoglycans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007795     DOI: 10.1074/jbc.M007917200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  The Tyrosine Sulfate Domain of Fibromodulin Binds Collagen and Enhances Fibril Formation.

Authors:  Viveka Tillgren; Matthias Mörgelin; Patrik Önnerfjord; Sebastian Kalamajski; Anders Aspberg
Journal:  J Biol Chem       Date:  2016-09-15       Impact factor: 5.157

2.  The tyrosine sulfate-rich domains of the LRR proteins fibromodulin and osteoadherin bind motifs of basic clusters in a variety of heparin-binding proteins, including bioactive factors.

Authors:  Viveka Tillgren; Patrik Onnerfjord; Lisbet Haglund; Dick Heinegård
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

Review 3.  Fell-Muir Lecture: Proteoglycans and more--from molecules to biology.

Authors:  Dick Heinegård
Journal:  Int J Exp Pathol       Date:  2009-12       Impact factor: 1.925

4.  PRELP protein inhibits the formation of the complement membrane attack complex.

Authors:  Kaisa E Happonen; Camilla Melin Fürst; Tore Saxne; Dick Heinegård; Anna M Blom
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 5.  The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis.

Authors:  A Hultgårdh-Nilsson; J Borén; S Chakravarti
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

6.  AAV-mediated expression of human PRELP inhibits complement activation, choroidal neovascularization and deposition of membrane attack complex in mice.

Authors:  M T Birke; E Lipo; M Adhi; K Birke; R Kumar-Singh
Journal:  Gene Ther       Date:  2014-03-27       Impact factor: 5.250

7.  S-Nitrosylation of secreted recombinant human glypican-1.

Authors:  Gabriel Svensson; Katrin Mani
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

8.  A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan.

Authors:  Stuart W Tompson; Barry Merriman; Vincent A Funari; Maryline Fresquet; Ralph S Lachman; David L Rimoin; Stanley F Nelson; Michael D Briggs; Daniel H Cohn; Deborah Krakow
Journal:  Am J Hum Genet       Date:  2008-12-24       Impact factor: 11.025

Review 9.  Sequence features, structure, ligand interaction, and diseases in small leucine rich repeat proteoglycans.

Authors:  Norio Matsushima; Hiroki Miyashita; Robert H Kretsinger
Journal:  J Cell Commun Signal       Date:  2021-04-15       Impact factor: 5.782

10.  The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis.

Authors:  Nadia Rucci; Anna Rufo; Marina Alamanou; Mattia Capulli; Andrea Del Fattore; Emma Ahrman; Daria Capece; Valeria Iansante; Francesca Zazzeroni; Edoardo Alesse; Dick Heinegård; Anna Teti
Journal:  J Cell Biol       Date:  2009-11-30       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.